IL-15 signaling via cis- and trans-presentation to progenitor-exhausted CD8⁺ T cells enhances radio-immunotherapy efficacy in ESCC.

ABSTRACT:

Background

Concurrent chemoradiotherapy (CRT) combined with PD-1/PD-L1 targeting immunotherapy (IM) has emerged as a promising treatment for locally advanced esophageal squamous cell carcinoma (ESCC). However, individual responses to this treatment vary, highlighting the need for predictive biomarkers to improve therapeutic efficacy. Interleukin-15 (IL-15) has shown potential in enhancing anti-tumor immunity, but its role in ESCC remains poorly defined.

Methods

We analyzed clinical cohorts of ESCC patients who underwent radiotherapy (RT) and IM, utilizing blood and tissue samples collected pre- and during treatment. A multi-omics approach combining ELISA, flow cytometry, single-cell RNA sequencing, and spatial analysis was employed to investigate the role of IL-15 within the

SUBMITTER: You Y 

PROVIDER: S-EPMC12771779 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature